Edition:
United States

Amicus Therapeutics Inc (FOLD.OQ)

FOLD.OQ on NASDAQ Stock Exchange Global Market

10.61USD
10 Dec 2018
Change (% chg)

$0.69 (+6.96%)
Prev Close
$9.92
Open
$9.93
Day's High
$10.69
Day's Low
$9.93
Volume
1,254,377
Avg. Vol
772,985
52-wk High
$17.60
52-wk Low
$9.66

Chart for

About

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with... (more)

Overall

Beta: 1.47
Market Cap(Mil.): $1,957.26
Shares Outstanding(Mil.): 189.29
Dividend: --
Yield (%): --

Financials

  FOLD.OQ Industry Sector
P/E (TTM): -- 95.96 30.88
EPS (TTM): -1.88 -- --
ROI: -49.49 0.60 13.80
ROE: -83.55 -2.18 15.29

Amicus sets $315,000 price for new Fabry disease treatment

Amicus Therapeutics on Monday set an average price of $315,000 per year for its newly approved Fabry disease treatment, a price it believes is below that of the main existing treatment in the United States.

Aug 13 2018

UPDATE 1-Amicus sets $315,000 price for new Fabry disease treatment

Aug 13 Amicus Therapeutics on Monday set an average price of $315,000 per year for its newly approved Fabry disease treatment, a price it believes is below that of the main existing treatment in the United States.

Aug 13 2018

Amicus sets $315,000 price for new Fabry disease treatment

Aug 13 Amicus Therapeutics priced its new Fabry disease treatment at an average $315,000 per year in the United States, the company said on Monday.

Aug 13 2018

Amicus Therapeutics receives U.S. approval for Fabry disease drug

U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

Aug 10 2018

UPDATE 2-Amicus Therapeutics receives U.S. approval for Fabry disease drug

Aug 10 U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

Aug 10 2018

Amicus Therapeutics receives U.S. approval for Fabry disease drug

Aug 10 U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

Aug 10 2018

Earnings vs. Estimates